These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 21782804)

  • 1. Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype.
    Kwon MJ; On YK; Huh W; Ko JW; Kim DK; Kim JS; Lee SY
    Clin Chim Acta; 2011 Nov; 412(23-24):2343-5. PubMed ID: 21782804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.
    Goto T; Miura M; Murata A; Terata K; Uno T; Yamamoto K; Abe Y
    Clin Chim Acta; 2010 Sep; 411(17-18):1375-7. PubMed ID: 20420818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
    McMillin GA; Melis R; Wilson A; Strong MB; Wanner NA; Vinik RG; Peters CL; Pendleton RC
    Ther Drug Monit; 2010 Jun; 32(3):338-45. PubMed ID: 20386359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement.
    Lee SY; Nam MH; Kim JS; Kim JW
    J Korean Med Sci; 2007 Jun; 22(3):557-9. PubMed ID: 17596671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
    Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
    Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genetic and bioenvironmental factors associated with warfarin response in Colombian patients].
    Isaza C; Beltrán L; Henao J; Porras G; Pinzón A; Vallejos A; Machado J
    Biomedica; 2010; 30(3):410-20. PubMed ID: 21713343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
    Siddiqi A; Khan DA; Khan FA; Naveed AK
    Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Warfarin in the treatment of antiphospholipid syndrome].
    Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
    Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
    Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V
    Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.
    Avery PJ; Jorgensen A; Hamberg AK; Wadelius M; Pirmohamed M; Kamali F;
    Clin Pharmacol Ther; 2011 Nov; 90(5):701-6. PubMed ID: 22012312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9.
    Lee SY; Kim JS; Kim JW
    Yonsei Med J; 2005 Dec; 46(6):843-6. PubMed ID: 16385662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.
    Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y
    Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients].
    Siguret V; Gouin I; Golmard JL; Geoffroy S; Andreux JP; Pautas E
    Rev Med Interne; 2004 Apr; 25(4):271-4. PubMed ID: 15050794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.
    Dickinson GL; Lennard MS; Tucker GT; Rostami-Hodjegan A
    Br J Clin Pharmacol; 2007 Jul; 64(1):14-26. PubMed ID: 17298479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients.
    Lee S; Kim JM; Chung CS; Cho KJ; Kim JH
    Arch Pharm Res; 2003 Nov; 26(11):967-72. PubMed ID: 14661864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probable interaction between warfarin and torsemide.
    Bird J; Carmona C
    Ann Pharmacother; 2008 Dec; 42(12):1893-8. PubMed ID: 19017829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible interaction between warfarin and Lycium barbarum L.
    Lam AY; Elmer GW; Mohutsky MA
    Ann Pharmacother; 2001 Oct; 35(10):1199-201. PubMed ID: 11675844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current challenges in personalizing warfarin therapy.
    McMillin GA; Vazquez SR; Pendleton RC
    Expert Rev Clin Pharmacol; 2011 May; 4(3):349-62. PubMed ID: 22114781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.